Format:
Online-Ressource (X, 319 p. 34 illus., 26 illus. in color, digital)
ISBN:
9781461446668
Series Statement:
SpringerLink
Content:
Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
Note:
Description based upon print version of record
,
Advances in Biology and Therapy of Multiple Myeloma; Preface; Contents; Part I: Myeloma Molecular Pathways and Cell Signaling; Chapter 1: Genomic Strategies Determining Progression from MGUS to Multiple Myeloma; 1.1 Myeloma; 1.2 The Genetics of Plasma Cell Disorders; 1.2.1 Translocation t(11; 14); 1.2.2 Translocation t(4; 14); 1.2.3 Translocation t(14; 16) and Other MAF Translocations; 1.2.4 Deletion of Chromosome 13; 1.2.5 Deletion of 17p13; 1.2.6 Chromosome 1; 1.2.7 RAS Mutations; 1.2.8 Gene Expression Pro fi ling; 1.2.9 High-Throughput Mutation Analysis; 1.2.10 Epigenetic Factors
,
1.2.11 Subclonal Heterogeneity1.3 Evaluating Disease Progression; 1.3.1 In Vitro and in Vivo Models of Disease Progression; 1.3.2 Progression of the Disease, Intrinsic Versus Extrinsic; 1.3.3 Clinical Monitoring for Progression; 1.3.4 Public Health Implications; 1.4 Conclusion; References; Chapter 2: Prognostic Implication of Genetic Changes (Cytogenetics, and FISH, Gains and Losses of DNA by SNP Array and aCGH) in Risk Strati fi cation in Myeloma; 2.1 De fi nitions and Technical Aspects; 2.2 Speci fi c Chromosomal Changes; 2.2.1 Aneuploidy; 2.2.2 Chromosome 13 Abnormalities
,
2.2.3 Translocations Involving the 14q32 Region2.2.4 Deletions 17p; 2.2.5 Abnormalities of the 1q Region; 2.3 Practical Use of Cytogenetic Data in Routine Practice; 2.4 Genomic Abnormalities in MM; 2.4.1 Minimal Common Regions of Interest with Prognostic Value; 2.4.2 Genes of Interest Residing in MGCL; 2.4.3 Multivariate Analysis of Lesions Independent of Risk Strati fi cation; 2.5 Conclusion; References; Chapter 3: Advances in Multiple Myeloma Gene-Expression Pro fi ling; 3.1 Historical Perspective; 3.2 Microarray Pro fi ling in MM; 3.2.1 MM Cell Procurement Techniques
,
3.2.2 Early GEP-Based Studies3.2.3 Early GEP-Based Discoveries of MM Genetic Anomalies; 3.3 GEP-Based MM Classi fi cation; 3.3.1 MS Class; 3.3.2 MF Class; 3.3.3 CD-1 and CD-2 Classes; 3.3.4 HY Class; 3.3.5 LB Class; 3.3.6 PR Class; 3.3.7 Classi fi cation Outliers; 3.4 MM-Speci fi c Genetic Features and GEP; 3.4.1 GEP and Hyperdiploid Disease; 3.4.2 GEP and Chromosome 13 Deletion; 3.4.3 GEP and Gains of Chromosome 1q; 3.4.4 GEP and Deletion of 17p13/TP53; 3.5 GEP-Based MM Risk Strati fi cation; 3.5.1 GEP-De fi ned High-Risk MM; 3.5.2 Progression of Low-Risk to High-Risk at Relapse
,
3.5.3 GEP and the Centrosome Index3.5.4 GEP and CD200; 3.6 GEP in MM Therapeutic Decision-Making; 3.6.1 GEP and Cancer-Testis Antigen Expression in MM; 3.6.2 GEP and IGF Signaling; 3.6.3 Pharmacogenomic Studies of Short-Term In Vivo Exposure; 3.7 Conclusions; References; Chapter 4: Growth Factors in Multiple Myeloma; 4.1 Myeloma Cell Growth Factors; 4.1.1 MMC Autocrine Growth Factors; 4.1.2 Bone Marrow Stromal Cell-Produced Growth Factors; 4.1.3 Osteoclast-Produced Growth Factors; 4.1.4 BM Endothelial Cell-Produced Growth Factors; 4.1.5 BM Immune Cell-Produced Growth Factors
,
4.1.6 Adipocyte-Produced Growth Factors
,
Genomic strategies determining progressions from MGUS to Multiple Myeloma -- Prognostic implication of Genetic changes (Cytogenetics, and FISH, gains and losses of DNA by SNP array and aCGH) in risk stratification in myeloma -- Advances in MM gene expression profiling -- Growth factors in MM -- Role of Wnt signaling pathways in multiple myeloma pathogenesis -- mTOR pathway in multiple myeloma -- Jak/STAT signaling in the pathogenesis and treatment of multiple myeloma -- Role of extracellular matrix in myeloma biology -- Osteoclasts: Potential target for blocking microenvironmental support of myeloma -- Targeting the BAFF/APRIL cytokine network in multiple myeloma -- Role of Osteoblast in myeloma pathology -- Migration and homing in Multiple Myeloma -- Genes and proteins of myeloma endothelial cells to search specific targets of the tumor vasculature -- Epigenetic regulation of myeloma within its bone marrow microenvironment -- Targeting mulitple myeloma tumor angiogenesis: focus on VEGF -- Novel in vivo model in myeloma -- Index.
Additional Edition:
ISBN 9781461446651
Additional Edition:
Buchausg. u.d.T. ISBN 978-1-461-44665-1
Language:
English
DOI:
10.1007/978-1-4614-4666-8
URL:
Volltext
(lizenzpflichtig)
Bookmarklink
